Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6841 to 6855 of 8320 results

  1. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued Reference number: GID-TA10569

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

    Technology appraisal guidance
    Discontinued

  3. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued Reference number: GID-TA10574

    Technology appraisal guidance
    Discontinued

  4. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development Reference number: GID-TA10577 Expected publication date:  21 April 2021

    Technology appraisal guidance
    In development

  5. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued Reference number: GID-TA10329

    Technology appraisal guidance
    Discontinued

  6. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued Reference number: GID-TA10332

    Technology appraisal guidance
    Discontinued

  7. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued Reference number: GID-TA10337

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued Reference number: GID-TA10338

    Technology appraisal guidance
    Discontinued

  9. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued Reference number: GID-TA10341

    Technology appraisal guidance
    Discontinued

  10. Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy [ID1147]

    Discontinued Reference number: GID-TA10343

    Technology appraisal guidance
    Discontinued

  11. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  12. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued Reference number: GID-TA10353

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued Reference number: GID-TA10354

    Technology appraisal guidance
    Discontinued

  14. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued Reference number: GID-TA10355

    Technology appraisal guidance
    Discontinued

  15. Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]

    Discontinued Reference number: GID-TA10356

    Technology appraisal guidance
    Discontinued